These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
237 related items for PubMed ID: 29768950
1. Statins in liver disease: not only prevention of cardiovascular events. Magan-Fernandez A, Rizzo M, Montalto G, Marchesini G. Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):743-744. PubMed ID: 29768950 [No Abstract] [Full Text] [Related]
2. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C. Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [Abstract] [Full Text] [Related]
3. Under-prescription of statins in patients with non-alcoholic fatty liver disease. Del Ben M, Baratta F, Polimeni L, Pastori D, Loffredo L, Averna M, Violi F, Angelico F. Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):161-167. PubMed ID: 27914698 [Abstract] [Full Text] [Related]
4. Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed? Athyros VG, Katsiki N, Mikhailidis DP. Curr Vasc Pharmacol; 2016 Feb; 14(4):313-5. PubMed ID: 27173023 [No Abstract] [Full Text] [Related]
5. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. Dig Liver Dis; 2015 Jan; 47(1):4-11. PubMed ID: 25224698 [Abstract] [Full Text] [Related]
6. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ. Aliment Pharmacol Ther; 2020 Aug; 52(4):619-636. PubMed ID: 32638417 [Abstract] [Full Text] [Related]
18. [Optimization of long-term treatment with rosuvastatin of patients with myocardial infarction in combination with non-alcoholic steatohepatitis]. Skrypnyk IM, Dubrovins'ka TV. Lik Sprava; 2014 Oct; (5-6):113-21. PubMed ID: 25906659 [Abstract] [Full Text] [Related]